Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

Table 1 Clinical characteristics of study population

Characteristic	Total (n = 303)	Australia (n = 210)		Oxford (n = 93)
Gender
Female, n (%)	143 (47)	95 (45)		48 (52)
Median age VDZ given (range, yr)	35 (16-84)	36 (19-78)		35 (16-84)
Median disease duration (range, yr)	6 (0.2-48)	7 (1-48)		5.4 (0.2-39.2)
Montreal classification, n (%)
Age
A1	34 (11)	33 (16)		1 (1)
A2	170 (56)	120 (57)		50 (54)
A3	99 (33)	57 (27)		42 (45)
Location
E1	18 (6)	15 (7)		3 (3)
E2	114 (38)	72 (34)		42 (45)
E3	170 (56)	122 (58)		48 (52)
Missing	1	1		0
Family History, n (%)	29 (12)	22 (15)		7 (7)
First degree	19	12		7
Second degree	10	10		0
None	212	126		86
Smoking, n
Never	226	140		86
Current	9	6		3
Ex smoker	45	41		4
Anti-TNF naïve, n (%)	182 (60)	122 (58.1)		60 (65)
Anti-TNF exposed, n (%)	121 (40)	88 (41.9)		33 (35)
Primary LOR	45 (15)	29 (13.8)		16 (17)
Secondary LOR	61 (20)	47 (22.4)		14 (15)
Side-effects	15 (5)	12 (5.7)		3 (3.2)
Steroids at VDZ initiation, n (%)	191 (63)	134 (64)		57 (61.2)
Prednisone	162 (53)	108 (51)		54 (58)
Budesonide	29 (10)	26 (12)		3 (3)
Immunomodulation at VDZ initiation, n (%)	175 (58)	135 (64)		40 (43)
AZA/6MP	136 (45)	108 (51)		28 (30)
Methotrexate	19 (6)	11 (5)		8 (9)
Tacrolimus	17 (6)	16 (8)		1 (1)
Others (Cyclo&Myco)	3 (1)	0		3 (3)
Mean Partial Mayo before VDZ initiation	5 (2-9)	6 (2-9)	5 (2-9)

VDZ: Vedolizumab; min: Minimum; max: Maximum; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response; Secondary LOR: Secondary loss of response; AZA: Azathioprine; 6MP: 6-mercaptopurine; Cyclo: Ciclosporine; Myco: Mycophenolate; Init, Initiation.